Anti-Human EGFR Recombinant Antibody (Futuximab) (CAT#: TAB-H35)

Figure 1 Antibodies Internalizes and Degrades EGFRvIII.

Quantification of EGFRvIII detected in spots after antibody treatment for the indicated periods.

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of neuro-oncology, 138(3), 489-498.

Figure 2 Antibodies Internalizes and Degrades EGFRvIII.

The cell line NR6M was treated with negative control mAb (Neg Ctrl mAb), futuximab, modotuximab, or Sym004 for 24 or 48 h, followed by harvest of cell lysates and detection of EGFRvIII by Western blot.

Figure 3 Effect of Sym004, and Its Components Futuximab and Modotuximab, in Subcutaneous Glioblastoma Xenograft Tumor Models.

EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.ournal of neuro-oncology, 138(3), 489-498.

Figure 4 Sym004 shows potent inhibition in Subcutaneous Glioblastoma Xenograft Tumor Models.

EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).

Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.rnal of neuro-oncology, 138(3), 489-498.